PF-3882845

• UNSPSC Description:

  PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM[1].

• Target Antigen:

  Mineralocorticoid Receptor; Progesterone Receptor

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-3882845.html

• Purity:

  99.90

• Solubility:

  DMSO : 10 mg/mL (ultrasonic;warming)

• Smiles:

  N#CC1=CC=C(N2N=C(C(C=CC(C(O)=O)=C3)=C3CC4)[C@H]4[C@@H]2C5CCCC5)C=C1Cl

• Molecular Weight:

  419.90

• References & Citations:

  [1]Meyers MJ, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem. 2010 Aug 26;53(16):5979-6002.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  1023650-66-9